Dashboard
Manage Tickers

AGIO AGIOS PHARMACEUTICALS, INC.

Nasdaq agios.com


$ 40.51 $ 0.51 (1.28 %)    

Wednesday, 05-Nov-2025 15:59:59 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 622.38 $ 4.94 (0.8 %)
DIA $ 473.04 $ 2.23 (0.47 %)
SPY $ 677.28 $ 2.47 (0.37 %)
TLT $ 89.01 $ -0.57 (-0.64 %)
GLD $ 365.20 $ 0.10 (0.03 %)
$ 40.51
$ 39.88
$ 37.77 x 2,777
$ 42.00 x 3
-- - --
$ 23.42 - $ 62.58
503,629
na
2.36B
$ 1.21
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-30-2025 09-30-2025 10-Q
2 07-31-2025 06-30-2025 10-Q
3 05-01-2025 03-31-2025 10-Q
4 02-13-2025 12-31-2024 10-K
5 10-31-2024 09-30-2024 10-Q
6 08-01-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 02-15-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 02-23-2023 12-31-2022 10-K
13 11-03-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 02-24-2022 12-31-2021 10-K
17 11-03-2021 09-30-2021 10-Q
18 07-29-2021 06-30-2021 10-Q
19 04-29-2021 03-31-2021 10-Q
20 02-25-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 07-30-2020 06-30-2020 10-Q
23 04-30-2020 03-31-2020 10-Q
24 02-19-2020 12-31-2019 10-K
25 10-31-2019 09-30-2019 10-Q
26 08-01-2019 06-30-2019 10-Q
27 05-02-2019 03-31-2019 10-Q
28 02-14-2019 12-31-2018 10-K
29 11-01-2018 09-30-2018 10-Q
30 08-02-2018 06-30-2018 10-Q
31 05-04-2018 03-31-2018 10-Q
32 02-14-2018 12-31-2017 10-K
33 11-01-2017 09-30-2017 10-Q
34 08-08-2017 06-30-2017 10-Q
35 05-04-2017 03-31-2017 10-Q
36 02-16-2017 12-31-2016 10-K
37 11-03-2016 09-30-2016 10-Q
38 08-08-2016 06-30-2016 10-Q
39 05-09-2016 03-31-2016 10-Q
40 02-26-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

earnings-scheduled-for-october-30-2025
Earnings Scheduled For October 30, 2025
10/30/2025 11:12:06

agios-pharmaceuticals-q3-eps-178-beats-191-estimate-sales-12880m-beat-10417m-estimate
Agios Pharmaceuticals Q3 EPS $(1.78) Beats...
10/30/2025 10:35:30

Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.78) per share which beat the analyst consensus estimate of...

earnings-outlook-for-agios-pharmaceuticals
Earnings Outlook For Agios Pharmaceuticals
10/29/2025 19:02:33

reported-earlier-agios-pharmaceuticals-receives-chmps-opinion-for-the-new-indication-for-pyrukynd-the-european-commission-will-now-review-the-chmps-opinion-with-the-final-decision-expected-by-early-2026
Reported Earlier: Agios Pharmaceuticals Re...
10/17/2025 15:27:48

CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceut...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
09/23/2025 12:09:16

hc-wainwright--co-reiterates-buy-on-agios-pharmaceuticals-maintains-56-price-target
HC Wainwright & Co. Reiterates Buy on Agio...
09/04/2025 16:04:25

HC Wainwright & Co. analyst Emily Bodnar reiterates Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and maintains $56 pri...

fda-delays-decision-on-agios-pharmaceuticals-blood-disorder-drug-for-expanded-use
FDA Delays Decision On Agios Pharmaceutica...
09/04/2025 14:49:53

Agios' Pyrukynd FDA review for thalassemia delayed to Dec. 7, 2025, after REMS submission addressing potential liver injury...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/04/2025 12:08:12

agios-pharmaceuticals-announces-pdufa-goal-date-for-pyrukynd-extended-by-three-months-to-dec-7
Agios Pharmaceuticals Announces PDUFA Goal...
09/04/2025 11:45:50

Core News & Articles
10 Health Care Stocks With Whale Alerts In...
08/21/2025 17:35:27

saudi-food-and-drug-authority-approves-agios-pyrukynd-for-adults-with-thalassemia
Saudi Food And Drug Authority Approves Agi...
08/04/2025 20:22:10

First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA's Breakthrough Medicines ProgramAgios partnered...

agios-pharmaceuticals-says-it-is-aware-of-the-securities-analyst-report-published-on-august-4-2025-detailing-recent-pyrukynd-data-from-the-us-fda-adverse-event-reporting-system-co-is-committed-to-delivering-safe-effective-treatments-for-patients-with-rare-diseases-and-will-continue-to-follow-our-established-rigorous-pharmacovigilance-processes-separately-on-august-4-2025-the-saudi-food-and-drug-authority-announced-that-it-has-approvedpyrukynd
Agios Pharmaceuticals Says It Is Aware Of ...
08/04/2025 18:53:07

-SEC Filing

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
08/04/2025 17:06:36

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
08/04/2025 12:08:38

agios-pharmaceuticals-q2-eps-193-misses-177-estimate-sales-12455m-beat-9537m-estimate
Agios Pharmaceuticals Q2 EPS $(1.93) Misse...
07/31/2025 10:32:25

Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.93) per share which missed the analyst consensus estimate ...

Core News & Articles
Earnings Scheduled For July 31, 2025
07/31/2025 08:32:50

scotiabank-maintains-sector-outperform-on-agios-pharmaceuticals-lowers-price-target-to-65
Scotiabank Maintains Sector Outperform on ...
07/28/2025 21:29:26

Scotiabank analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Sector Outperform and lowers the price...

b-of-a-securities-maintains-buy-on-agios-pharmaceuticals-lowers-price-target-to-51
B of A Securities Maintains Buy on Agios P...
07/22/2025 16:15:51

B of A Securities analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and lowers the price target...

agios-avanmzanite-sign-agreement-for-pan-european-partnership-for-pyrukynd-launch
Agios, Avanmzanite Sign Agreement For Pan-...
06/09/2025 12:44:47

PYRUKYND® (mitapivat) is a first-in-class pyruvate kinase (PK) activator, approved by the European Commission for adults with P...

agios-pharma-new-data-on-pk-activators-mitapivat-and-tebapivat-to-be-featured-in-oral-and-poster-presentations-during-eha-congress-2025
Agios Pharma: New Data On PK Activators, M...
05/14/2025 14:02:10

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering thera...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION